TGA registers Mounjaro in Australia

Australia's Therapeutic Goods Administration (TGA) approved Mounjaro, the brand name for tirzepatide, on December 22, 2022, and registered it the following day ^[1]. The approval covers adults with type 2 diabetes whose blood sugar is not well controlled, for use alongside diet and exercise ^[1].

The TGA cleared Mounjaro for two specific uses: as a standalone treatment when metformin cannot be used or is not tolerated, and as an add-on to other diabetes medicines ^[1]. The sponsor for the Australian registration is Eli Lilly Australia Pty Limited ^[1].

Tirzepatide works differently from single-hormone diabetes drugs. It is a long-acting molecule that activates two receptors at once: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) ^[1]. Both receptor types sit on cells in the pancreas, brain, heart, blood vessels, immune system, gut and kidneys, and GIP receptors are also found on fat cells ^[1]. According to the TGA's technical summary, tirzepatide binds strongly to both receptors, with GIP activity similar to the body's natural hormone and somewhat lower GLP-1 activity compared with the natural GLP-1 hormone ^[1]. The drug is built with a fatty acid attachment that lets it bind to albumin in the blood, which extends how long it stays active in the body ^[1].

The TGA said its approval decision rested on a review of manufacturing quality data, animal and lab studies, clinical trial results on safety and effectiveness, and a plan for managing risks after the drug reaches the market ^[1]. The agency concluded that the benefit-risk balance was favorable for the diabetes use it approved ^[1]. Six pen strengths were placed on Australia's register of therapeutic goods, ranging from 2.5 mg to 15 mg per 0.5 mL ^[1].

Why it matters for patients

This is an Australian regulatory record, not a US Food and Drug Administration action. It matters to US patients mainly as a marker of tirzepatide's international spread and as background on how the drug is described by regulators outside the United States. The approval covers type 2 diabetes, not weight management on its own, and it does not describe the drug's use under the Zepbound brand name, which is how tirzepatide is sold for weight loss in some markets ^[1].

The source document does not include any data on side effects, dosing schedules, cost, or comparisons with other diabetes drugs. It also does not say when Mounjaro became available to patients in Australian pharmacies after the December 23, 2022 registration date. Readers looking for information on tirzepatide's US approval history, its Zepbound weight-loss indication, or coverage and pricing details will need to look to other sources, since none of that is addressed in this TGA record ^[1].

What the document does make clear is the scientific basis regulators cited: tirzepatide's dual action on GIP and GLP-1 receptors, and its designed long half-life through albumin binding ^[1]. That dual-hormone mechanism is the same one behind tirzepatide's use in other countries and under other brand names, though this specific record only addresses the Australian diabetes approval ^[1].

What happens next

The source material does not describe what came after registration, such as when Mounjaro reached Australian patients, whether additional strengths or indications were later added to the country's therapeutic goods register, or how the drug's availability there compares with its rollout in the United States. Those details are not yet known from the information provided here.